Trial Profile
A Multi-center Study of the Safety and Effect on Disease Activity of Tocilizumab (TCZ) in Combination With MTX Versus Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis, With Inadequate Response to MTX (Defined as DAS 28 > 3,2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms JUST-ACT
- Sponsors Roche
- 01 May 2020 Results published in the Clinical and Experimental Rheumatology
- 17 Sep 2018 Primary endpoint (Change in Disease Activity Score Based on 28-Joint Count (DAS28) From Week 16 to Week 28) has been met, according to the results published in the Clinical and Experimental Rheumatology
- 17 Sep 2018 Results published in the Clinical and Experimental Rheumatology